Physician profile
Dennis Delapp
NPI 1881699635
$3,116.65
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $1,040 · 2021: $827 · 2022: $227 · 2023: $72.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $335.95 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $327.36 | 2019-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $275.71 | 2019-2021 | |
| Amgen INC. | $260.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.33 | 2019-2021 | |
| Amarin Pharma, INC. | $237.84 | 2019-2021 | |
| Pfizer INC. | $230.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $175.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.73 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $100.31 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $99.88 | 2020-2021 | |
| Corcept Therapeutics | $96.73 | 2020-2023 | Korlym |
| Allergan, INC. | $95.05 | 2019-2020 | |
| Lilly USA, LLC | $79.66 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $77.67 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $76.97 | 2019-2021 | |
| Esperion Therapeutics, INC. | $66.97 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.95 | 2019-2020 | |
| Seqirus USA INC | $26.37 | 2019 | |
| Mannkind Corporation | $23.51 | 2019 | |
| Glaxosmithkline, LLC. | $22.78 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $21.29 | 2021 | |
| Astellas Pharma US INC | $16.82 | 2020 | |
| Hikma Pharmaceuticals USA | $16.02 | 2019 | |
| Phadia US INC. | $14.17 | 2021 | |
| Dexcom, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Delapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.